Sue’s practice focuses on the preparation and prosecution of U.S., international, and foreign patent applications. She also prepares legal opinions, including patentability, invalidity, infringement/non-infringement, and freedom-to-operate opinions. Additionally, she prepares and prosecutes trademark applications.
Sue specializes in biotechnical and medical patent applications, including applications relating to medical genetics, immunology, oncology, biochemistry, and plant biology. She has more than 10 years of experience preparing and prosecuting patent applications, and additionally, more than 10 years of research experience at some of the leading life science research institutions in the U.S. Sue has extensive research experience in the fields of cell and molecular biology, biochemistry, and genetics, including clinical diagnostics.
Sue joined Klarquist in 2007 as an associate and became partner in 2018.
J.D., summa cum laude, Lewis & Clark College of Law, 2007
Ph.D., Cell Biology, Duke University, 1996
B.A., Biology, College of Wooster, 1991
U.S. Patent and Trademark Office, 2007 (Reg. No. 60,432)
Life Sciences & Biotechnology Medical Devices & Diagnostics Chemical Plants Agriculture & Food Science Green Technology & Renewable Energy
Oregon Health & Science University Portland, Oregon
Senior Research Assistant, Department of Molecular and Medical Genetics, 2003 – 2005
Developed and implemented clinical diagnostic tests for human genetic diseases utilizing technologies such as denaturing high performance liquid chromatography, real-time PCR, and direct sequencing.
Research Assistant, Department of Endocrinology, 2000 – 2003
Participated in basic research studies in genetics of congenital heart disease, including human genetic analysis, biochemical studies of heart protein CRELD1, and analysis of CRELD1 knockout mouse line.
University of Texas Southwestern Medical Center Dallas, Texas
Research Associate, Howard Hughes Medical Institute (post-doctoral fellow), 1996 – 1999
Involved in basic research on genetics of retinal degeneration, including creation and analysis of knockout mouse lines, mutation screening in human subjects with retinal degeneration, and biochemical studies of retinal guanylyl cyclase activity.
Durham, North Carolina
Graduate Research Assistant, Department of Cell Biology, 1991 – 1996
Participated in basic research on biochemical function of dopamine receptors, focused on signal transduction activity of the dopamine D2 and D3 receptors. Extensive experience in biochemical assays of second messenger signaling in cultured cell lines.
Member, Multnomah Bar Association
Member, Legal Employer Engagement Committee, Convocation on Equality, Oregon State Bar, 2010 – 2013
Member, Association of University Technology Managers
Mentor, Lewis & Clark Northwestern School of Law
Presentations & Publications
Graf, Susan Walmsley, “Improving Patent Quality Through Identification of Relevant Prior Art: Approaches to Increase Information Flow to the Patent Office”, 11 Lewis & Clark Law Review 495 (2007).
Robinson, S.W., Morris, C.D., Goldmuntz, E., Reller, M.D., Jones, M.A., Steiner, R.D., and Maslen, C.L. Missense mutations in CRELD1 are associated with cardiac atrioventricular septal defects. Am. J. Hum. Genet. 72:1047-1052 (2003).
Robinson, S. W., Dinulescu, D. M., and Cone, R. D. Genetic models of obesity and energy balance in the mouse. Ann. Rev. Genet. 34:687-745 (2000).
Robinson, S. W. and Garbers, D. L. Genetic models to study guanylyl cyclase function. Meth. Enzymol. 316:558-564 (2000).
Yang, R.-B., Robinson, S. W., Xiong, W.-H., Yau, K.-W., Birch, D. G., and Garbers, D. L. Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. J. Neurosci. 19:5889-5897 (1999).
Robinson, S. W. and Caron, M. G. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol. Pharmacol. 52:508-514 (1997).
Robinson, S. W. and Caron, M. G. Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells. J. Neurochem. 67:212-219 (1996).
Robinson, S. W., Jarvie, K. R., and Caron, M. G. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains. Mol. Pharmacol. 46:352-356 (1994).